IL2 and metastatic melanoma: Due to its immunostimulatory activity, high-dose IL-2 was tested in patients with cancer and became the first cytokine approved by the FDA for the treatment of metastatic renal cell carcinoma and metastatic melanoma in 1992 and 1998, respectively (103, 104).